Table 3.
Patient and tumor characteristics of patients who were metastatic at primary diagnosis or who developed recurrent disease stratified by PIK3CA mutation status.
| Characteristic | Total cohort (N = 197) |
Wild type (N= 135) |
PIK3CA Mutated (N = 62) |
P value* | |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | |||
| Age | |||||
| ≤ 50 | 84 (43%) | 67 (50%) | 17 (27%) | ||
| > 50 | 96 (49%) | 54 (40%) | 42 (68%) | < 0.001 | |
| Unknown | 17 (9%) | 14 (10%) | 3 (5%) | ||
| Menopausal status | |||||
| Pre | 43 (46%) | 31 (23%) | 12 (19%) | ||
| Post | 48 (51%) | 27 (20%) | 21 (34%) | 0.12 | |
| Unknown | 3 (3%) | 77 (57%) | 29 (47%) | ||
| Race | |||||
| Caucasian | 170 (86%) | 115 (85%) | 55 (89%) | ||
| Black | 15 (8%) | 12 (9%) | 3 (5%) | ||
| Unknown or other | 12 (6%) | 8 (6%) | 4 (6%) | ||
| Tumor size | |||||
| 0 –2 cm | 46 (23%) | 34 (25%) | 12 (19%) | ||
| 2.1 –5 cm | 54 (27%) | 36 (27%) | 18 (29%) | ||
| > 5 cm | 14 (7%) | 11 (8%) | 3 (5%) | 0.65 | |
| Unknown or NA | 83 (42%) | 54 (40%) | 29 (47%) | ||
| Positive lymph nodes | |||||
| 0 | 56 (28%) | 35 (26%) | 21 (34%) | ||
| 1 –3 | 53 (27%) | 35 (26%) | 18 (29%) | ||
| > 3 | 50 (25%) | 38 (28%) | 12 (19%) | 0.31 | |
| Unknown or NA | 38 (19%) | 27 (20%) | 11 (18%) | ||
| Histologic subtype | |||||
| Ductal | 176 (93%) | 120 (93%) | 56 (92%) | ||
| Lobular | 10 (5%) | 7 (5%) | 3 (5%) | ||
| Other | 4 (2%) | 2 (2%) | 2 (3%) | 0.715 | |
| Histologic Grade | |||||
| Low | 19 (10%) | 10 (7%) | 9 (15%) | ||
| Intermediate | 82 (42%) | 49 (36%) | 33 (53%) | ||
| High | 89 (45%) | 70 (52%) | 19 (31%) | 0.01 | |
| Unknown or NA | 7 (4%) | 6 (4%) | 1 (2%) | ||
| ER | |||||
| Postive | 137 (70%) | 88 (65%) | 49 (79%) | ||
| Negative | 49 (25%) | 41 (30%) | 8 (13%) | 0.011 | |
| Unknown | 11 (6%) | 68 (50%) | 5 (8%) | ||
| PR | |||||
| Positive | 114 (58%) | 75 (56%) | 39 (63%) | ||
| Negative | 69 (35%) | 52 (39%) | 17 (27%) | 0.17 | |
| Unknown | 14 (7%) | 4 (3%) | 6 (10%) | ||
| HER2 | |||||
| positive | 29 (15%) | 23 (17%) | 6 (10%) | ||
| negative | 143 (73%) | 98 (73%) | 45 (73%) | 0.18 | |
| Intermediate or Unknown | 25 (13%) | 14 (10%) | 11 (18%) | ||
| Receptor status | |||||
| ER+ or PR+/HER2− | 110 (56%) | 71 (53%) | 39 (63%) | ||
| ER+ or PR+/HER2+ | 17 (9%) | 14 (10%) | 3 (5%) | ||
| ER−and PR−/HER2+ | 11 (6%) | 9 (7%) | 2 (3%) | ||
| ER−and PR−/HER2− | 33 (17%) | 27 (20%) | 6 (10%) | ||
| Other | 26 (13%) | 14 (10%) | 12 (19%) | 0.081 | |
| Clinical trial participant | |||||
| yes | 62 (31%) | 38 (28%) | 24 (39%) | ||
| No | 133 (68%) | 95 (70%) | 38 (61%) | 0.16 | |
| Unknown | 2 (1%) | 2 (1%) | 0 (0%) | ||
| PI3K specific trial | |||||
| yes | 40 (20%) | 17 (13%) | 23 (37%) | ||
| No | 22 (11%) | 21 (16%) | 1 (2%) | < 0.001 | |
| NA | 135 (69%) | 97 (72%) | 38 (62%) | ||
| Metastatic at diagnosis | |||||
| yes | 44 (22%) | ||||
| No | 151 (77%) | ||||
| Unknown | 2 (1%) | ||||
Note: "Unknown," "other," or "NA" not included in p value calculation.